Wave Life Sciences (WVE) Jumps Almost 15% Following News of an Offering
Wave Life Sciences (WVE) ended the trading day up 14.66%. The positive trading day follows news that WVE priced an underwritten offering to raise $70M at a premium of 7.5%.
Wave Life Sciences is a clinical-stage genetic medicines company and housed in the PRISM Gene Therapy Index, which is up 2.2% for the day.
WVE’s press release mentions that RA Capital and other notable growth and life science investors participated in the Offering and the Offering is expected to close on June 16th, 2022.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.